Stockscreener 앱 받기
1.40
1.45%
0.02
시간 외 거래:
1.40
전일 마감가:
$1.38
열려 있는:
$1.37
하루 거래량:
37,595
Relative Volume:
0.04
시가총액:
$68.80M
수익:
$134.60K
순이익/손실:
$-11.81M
주가수익비율:
-5.8115
EPS:
-0.2409
순현금흐름:
$-10.05M
1주 성능:
+6.87%
1개월 성능:
-10.26%
6개월 성능:
+12.00%
1년 성능:
-33.33%
1일 변동 폭
$1.37
$1.415
1주일 범위
$1.2931
$1.415
52주 변동 폭
$1.13
$2.08
Medicinova Inc Stock (MNOV) Company Profile
명칭
Medicinova Inc
전화
858-373-1500
주소
4275 EXECUTIVE SQUARE, LA JOLLA, CA
MNOV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.40 | 67.82M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-10 | 개시 | Maxim Group | Buy |
| 2019-03-25 | 재개 | B. Riley FBR | Buy |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 개시 | Credit Suisse | Outperform |
| 2013-01-04 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-24 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2011-10-18 | 재확인 | MLV Capital | Buy |
| 2011-06-22 | 개시 | Global Hunter Securities | Buy |
| 2010-05-12 | 개시 | Wedbush | Outperform |
| 2008-11-12 | 재확인 | Ladenburg Thalmann | Buy |
| 2008-05-15 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 개시 | Punk, Ziegel & Co | Buy |
모두보기
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Lucid Cap Mkts - MarketBeat
MediciNova, Inc. Provides Shareholder Update on Clinical Trials and Strategic Developments for 2026 - Quiver Quantitative
2026 New Year’s Greetings from the CEO - The Manila Times
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – What’s Next? - Defense World
MNOVProspectus Filed Pursuant to Rule 424(b)(5) (424b5) - ADVFN
Retail Trends: Is MediciNova Inc stock a top pick in earnings seasonWeekly Profit Recap & High Conviction Buy Zone Picks - moha.gov.vn
4875.T Jumps 8.7% Today: Positive Momentum in Biotech - Meyka
MediciNova enters $50 million equity distribution agreement with Lucid Capital - Investing.com Nigeria
MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets - MarketScreener
Medicinova IncOn Dec 29, Entered $50 Million Equity Distribution Agreement With Lucid Capital Markets- SEC Filing - TradingView — Track All Markets
MediciNova Establishes Flexible At-The-Market Equity Program - TipRanks
MediciNova enters $50 million equity distribution agreement with Lucid Capital By Investing.com - Investing.com South Africa
MediciNova Signs Equity Distribution Agreement With Lucid Capital Markets - TradingView — Track All Markets
Form 424B5 MEDICINOVA INC - StreetInsider
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decline in Short Interest - MarketBeat
Bank Watch: Why MediciNova Inc. stock could benefit from AI revolutionTrade Analysis Report & AI Driven Stock Price Forecasts - moha.gov.vn
Is MediciNova Inc. stock a top pick in earnings seasonWeekly Investment Summary & Growth Focused Entry Point Reports - Bölüm Sonu Canavarı
Why MediciNova Inc. stock could benefit from AI revolutionQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Will MediciNova Inc. stock outperform value stocksDollar Strength & Real-Time Stock Movement Alerts - DonanımHaber
MediciNova (NASDAQ:MNOV) Receives Buy Rating from D. Boral Capital - Defense World
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
Aug Swings: Why MediciNova Inc. stock could benefit from AI revolution2025 Technical Overview & Verified Short-Term Plans - Улправда
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
How MediciNova Inc. stock performs in rising dollar environmentEarnings Performance Report & Community Shared Stock Ideas - Улправда
MediciNova completes enrollment in chemotherapy neuropathy trial By Investing.com - Investing.com Nigeria
MNOV: Analyst Jason Kolbert Maintains 'Buy' Rating with $9 Price - GuruFocus
D. Boral Capital Reaffirms Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug - marketscreener.com
MediciNova completes enrollment in chemotherapy neuropathy trial - Investing.com India
MediciNova, Inc. Completes Patient Enrollment in Phase 2 OXTOX Study for MN-166 in Metastatic Colorectal Cancer Patients - Quiver Quantitative
MediciNova Announces Completion of Patient Enrollment - GlobeNewswire
Bank Watch: Will MediciNova Inc stock beat EPS estimatesJuly 2025 Breakouts & Community Driven Trade Alerts - moha.gov.vn
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Here’s What Happened - Defense World
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Free cash flow per share of MediciNova, Inc. – TSE:4875 - TradingView — Track All Markets
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - The Manila Times
MediciNova completes enrollment in phase 2b/3 ALS clinical trial By Investing.com - Investing.com UK
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Medicinova Inc (MNOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):